These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 11897095)

  • 21. Mu and delta opioid-stimulated [35S]GTP gamma S binding in brain and spinal cord of polyarthritic rats.
    Cichewicz DL; Cox ML; Welch SP; Selley DE; Sim-Selley LJ
    Eur J Pharmacol; 2004 Nov; 504(1-2):33-8. PubMed ID: 15507218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 5-HT-stimulated [35S]guanosine-5'-O-(3-thio)triphosphate binding as an assay for functional activation of G proteins coupled with 5-HT1B receptors in rat striatal membranes.
    Odagaki Y; Toyoshima R
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Feb; 372(5):335-45. PubMed ID: 16491386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of chronic social stress on delta-opioid receptor function in the rat.
    Pohorecky LA; Skiandos A; Zhang X; Rice KC; Benjamin D
    J Pharmacol Exp Ther; 1999 Jul; 290(1):196-206. PubMed ID: 10381776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abundant expression of mu and delta opioid receptor mRNA and protein in the cerebellum of the fetal, neonatal, and adult rat.
    Mrkusich EM; Kivell BM; Miller JH; Day DJ
    Brain Res Dev Brain Res; 2004 Feb; 148(2):213-22. PubMed ID: 14766199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein.
    Alt A; McFadyen IJ; Fan CD; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2001 Jul; 298(1):116-21. PubMed ID: 11408532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COMT Val108/158Met genotype affects the mu-opioid receptor system in the human brain: evidence from ligand-binding, G-protein activation and preproenkephalin mRNA expression.
    Berthele A; Platzer S; Jochim B; Boecker H; Buettner A; Conrad B; Riemenschneider M; Toelle TR
    Neuroimage; 2005 Oct; 28(1):185-93. PubMed ID: 16040257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.
    Chen L; Togasaki DM; Langston JW; Di Monte DA; Quik M
    Neuroscience; 2005; 132(2):409-20. PubMed ID: 15802193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. mu-Opioid receptor-stimulated guanosine-5'-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy.
    Selley DE; Sim LJ; Xiao R; Liu Q; Childers SR
    Mol Pharmacol; 1997 Jan; 51(1):87-96. PubMed ID: 9016350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. G protein activation by endomorphins in the mouse periaqueductal gray matter.
    Narita M; Mizoguchi H; Narita M; Dun NJ; Hwang BH; Endoh T; Suzuki T; Nagase H; Suzuki T; Tseng LF
    J Biomed Sci; 2000; 7(3):221-5. PubMed ID: 10810240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autoradiographic mapping of dopamine-D2/D3 receptor stimulated [35S]GTPgammaS binding in the human brain.
    Sóvágó J; Makkai B; Gulyás B; Hall H
    Eur J Neurosci; 2005 Jul; 22(1):65-71. PubMed ID: 16029196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opioid receptors in the human cerebellum: evidence from [11C]diprenorphine PET, mRNA expression and autoradiography.
    Schadrack J; Willoch F; Platzer S; Bartenstein P; Mahal B; Dworzak D; Wester HJ; Zieglgänsberger W; Tölle TR
    Neuroreport; 1999 Feb; 10(3):619-24. PubMed ID: 10208600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential knockdown of delta-opioid receptor subtypes in the rat brain by antisense oligodeoxynucleotides targeting mRNA.
    Negri L; Lattanzi R; Borsodi A; Toth G; Salvadori S
    Antisense Nucleic Acid Drug Dev; 1999 Apr; 9(2):203-11. PubMed ID: 10355826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Agonist, antagonist, and inverse agonist characteristics of TIPP (H-Tyr-Tic-Phe-Phe-OH), a selective delta-opioid receptor ligand.
    Martin NA; Ruckle MB; VanHoof SL; Prather PL
    J Pharmacol Exp Ther; 2002 May; 301(2):661-71. PubMed ID: 11961071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors.
    Olianas MC; Concas D; Onali P
    Br J Pharmacol; 2006 Feb; 147(4):360-70. PubMed ID: 16402046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mu opioid receptor coupling to Gi/o proteins increases during postnatal development in rat brain.
    Talbot JN; Happe HK; Murrin LC
    J Pharmacol Exp Ther; 2005 Aug; 314(2):596-602. PubMed ID: 15860573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opioid binding sites in the guinea pig and rat kidney: radioligand homogenate binding and autoradiography.
    Dissanayake VU; Hughes J; Hunter JC
    Mol Pharmacol; 1991 Jul; 40(1):93-100. PubMed ID: 1649966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estrogen modulation of mu-opioid receptor-stimulated [35S]-GTP-gamma-S binding in female rat brain visualized by in vitro autoradiography.
    Acosta-Martinez M; Etgen AM
    Neuroendocrinology; 2002 Oct; 76(4):235-42. PubMed ID: 12411740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Micromolar concentrations of rimonabant directly inhibits delta opioid receptor specific ligand binding and agonist-induced G-protein activity.
    Zádor F; Kocsis D; Borsodi A; Benyhe S
    Neurochem Int; 2014 Feb; 67():14-22. PubMed ID: 24508403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes of GABA(A) receptor binding and subunit mRNA level in rat brain by infusion of subtoxic dose of MK-801.
    Kim HS; Choi HS; Lee SY; Oh S
    Brain Res; 2000 Oct; 880(1-2):28-37. PubMed ID: 11032987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ex vivo delta opioid receptor autoradiography: CNS receptor occupancy of two novel compounds over their antihyperalgesic dose range.
    Codd EE; Ma J; Zhang SP; Stone DJ; Colburn RW; Brandt MR; Chevalier KM; Zhu Y; Peng S; Cai C; Acton PD; Flores CM
    Pharmacol Biochem Behav; 2010 Aug; 96(2):130-5. PubMed ID: 20438745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.